Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 1;66:103308. doi: 10.1016/j.ebiom.2021.103308

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 1 — S. flexneri 2a LPS-Specific Serum IgG and IgA. (a) S. flexneri 2a LPS-specific serum IgG responses grouped by vaccinated subjects with or without per protocol shigellosis, and placebo subjects with or without per protocol shigellosis. (b) S. flexneri 2a LPS-specific serum IgG responses grouped by vaccinated subjects with or without consensus shigellosis, and placebo subjects with or without consensus shigellosis. (c) S. flexneri 2a LPS-specific serum IgA responses grouped by vaccinated subjects with or without consensus shigellosis, and placebo subjects with or without consensus shigellosis. * = significant difference as compared to baseline titres within the same treatment group/shigellosis outcome. Significance determined by repeated measures ANOVA of log-transformed titres with Bonferroni post-hoc test. (d) Percent efficacy against consensus shigellosis post-challenge in vaccinated subjects across increasing serum IgG and IgA ELISA endpoint titres.